A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome
2014
Medical Council
The potential of certain drugs to affect specific markers of progression of hypertension should be taken into account in the rational pharmacotherapy of arterial hypertension (AH) in patients with metabolic syndrome (MS). Pharmacodynamic effects of the beta-blocker (BB) nebivolol, the average daily dose 5,3 ± 2,5 mg, were studied in 29 patients with stage I - II hypertension with signs of MS (men - 15, women - 14; mean age 52, 4 ± 10,32 years). Nebivolol, along with a high antihypertensive
doi:10.21518/2079-701x-2014-12-100-105
doaj:846cb7c7f71e4bfe83ae30886d7883ec
fatcat:hleycwns3bejbbaphjvo6t3cl4